Marinus Pharmaceuticals price target lowered to $27 from $38 at H.C. Wainwright

H.C. Wainwright analyst Douglas Tsao lowered the firm’s price target on Marinus Pharmaceuticals to $27 from $38 and keeps a Buy rating on the shares post the Q3 results.